Enhanced repolarization capacity: New potential antiarrhythmic strategy based on hERG channel activation

Current Medicinal Chemistry

Volumn 18, Issue 24, 2011, Pages 3607-3621

  Szabo G ^a   Farkas, V ^a   Grunnet, M ^b,c   Mohacsi A ^d   Nanasi P P ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NEUROSEARCH A S   (Denmark)

^d Hungarian Institute of Cardiology   (Hungary)

Author keywords

Action potential; Cardiac electrophysiology; hERG channel activation; I Kr; Long QT syndrome; NS1643; Repolarization reserve

Indexed keywords

2 [2 (3,4 DICHLOROPHENYL) 2,3 DIHYDRO 1H ISOINDOL 5 YLAMINO] NICOTINIC ACID; 4 [3 (6 METHOXYQUINOLIN 4 YL) 3 OXOPROPYL] 1 [3 (2,3,5 TRIFLUOROPHENYL)PROP 2 YNYL]PIPERIDINE 3 CARBOXYLIC ACID; A 935142; ANTIARRHYTHMIC AGENT; AZAMILIDE; DOFETILIDE; FENAMIC ACID DERIVATIVE; FLUFENAMIC ACID; ICA 105574; KB 130015; MALLOTOXIN; METHOTREXATE; NIFEKALANT; NIFLUMIC ACID; NS 1643; NS 3623; PD 11778; PD 117780; PD 118057; PD 198986; PD 201583; PD 202091; PD 307243; PD 322388; POTASSIUM CHANNEL HERG; RPR 260243; UNCLASSIFIED DRUG;

AMPLITUDE MODULATION; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; GENE MUTATION; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE; HUMAN; ION CURRENT; NONHUMAN; QT INTERVAL; VOLTAGE CLAMP;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNELS; CRESOLS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MYOCYTES, CARDIAC; PHENYLUREA COMPOUNDS; POTASSIUM CHANNELS, INWARDLY RECTIFYING;

EID: 80052018704     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796642382     Document Type: Article

References (126)

1. Sanguinetti, M.C.; Keating, M.T. Role of delayed rectifier potassium channels in cardiac repolarization and arrhythmias. News Physiol. Sci., 1997, 12, 152-157.
2. + current in cardiac myocytes by dofetilide. J. Pharmacol. Exp. Ther., 1992, 262(2), 809-817.
3. Noble, D.; Tsien, R.W. Outward membrane currents activated in the plateau range of potentials in cardiac Purkinje fibres. J. Physiol., 1969, 200(1), 205-231.
4. + current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol., 1990, 96(1), 195-215. (Pubitemid 20227082)
5. K, by cadmium in cat ventricular myocytes. Am. J. Physiol., 1992, 262(1), C75-83.
6. Ks in electrical heterogeneity. Am. J. Physiol., 1995, 268(2), H604-613.
7. Ks. Am. J. Physiol., 1996, 271(6), H2477-2489.
8. Ks contributes to the longer action potential of the M cell. Circ. Res., 1995, 76(3), 351-365.
9. Ks in guineapig isolated ventricular myocytes. Exp. Physiol., 1996, 81(4), 587-603. (Pubitemid 26289832)
10. Ks in guinea-pig isolated ventricular myocytes. Exp. Physiol., 1996, 81(4), 605-621. (Pubitemid 26289833)
11. + current in heart: molecular basis, functional diversity, and contribution to repolarization. Acta Pharmacol Sin., 2004, 25(2), 137-145. (Pubitemid 38186160)
12. Perry, M.; Sanguinetti, M.; Mitcheson, J. Revealing the structural basis os action of hERG potassium channel activators and blockers. J. Physiol., 2010, 588.17, 3157-3167.
13. Smith, P.L.; Baukrowitz, T.; Yellen, G. The inward rectification mechanism of the hERG cardiac potassium channel. Nature, 1996, 379, 833-836. (Pubitemid 26067726)
14. + channel are involved in the activation- and deactivation-gating processes. J. Gen. Physiol., 2003, 121, 599-614. (Pubitemid 36682923)
15. Piper, D.R.; Varghese, A.; Sanguinetti, M.C.; Tristani-Firouzi, M. Gating currents associated with intramembrane charge displacement in hERG potassium channels. Proc. Natl. Acad. Sci. USA, 2003, 100, 10534-10539. (Pubitemid 37071913)
16. Piper, D.R.; Hinz, W.A.; Tallurri, C.K.; Sanguinetti, M.C.; Tristani-Firouzi, M. Regional specificity of hERG channel activation and inactivation gating. J. Biol. Chem., 2005, 280, 7206-7217. (Pubitemid 40341278)
17. Zhang, M.; Liu, J.; Tseng, G.N. Gating charges in the activation and inactivation processes of the ERG channel. J. Gen. Physiol., 2004, 124, 703-718. (Pubitemid 39628137)
18. Subbiah, R.N.; Clarke, C.E.; Smith, D.J.; Zhao, J.; Campbell, T.J.; Vandenberg, J.I. Molecular basis of slow activation of the human ether-a-go-go related gene potassium channel. J. Physiol., 2004, 558, 417-431. (Pubitemid 39117592)
19. + channel: the S4 domain is loosely packed and likely to be lipid exposed. J. Physiol., 2005, 569, 367-379. (Pubitemid 41830108)
20. Mitcheson, J.S.; Chen, J.; Lin, M.; Culberson, C.; Sanguinetti, M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. USA, 2000, 97, 12329-12333.
21. Chen, J.; Seebohm, G.; Sanguinetti, M.C. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of hERG and eag potassium channels. Proc. Natl. Acad. Sci. USA., 2002, 99, 12461-12466.
22. Seebohm, G. Activators of Cation Channels: Potential in Treatment of Channelopathies. Mol. Pharmacol., 2005, 67, 585-588. (Pubitemid 40365304)
23. Kr channel. J. Gen. Physiol., 1996, 107(5), 611-619.
24. + conductance. Proc. Natl. Acad. Sci. USA., 2009, 106(47), 20075-20080.
25. Iost, N.; Virág, L.; Opincariu, M., Szécsi, J., Varró, A.; Papp, J.G. Delayed rectifier potassium current in undiseased human ventricular myocytes. Cardiovasc. Res., 1998, 40(3), 508-515. (Pubitemid 28557291)
26. K,s in electrical heterogeneity. Am. J. Physiol., 1995, 268, H604-613.
27. Warmke, J.W.; Ganetzky, B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc. Natl. Acad. Sci. USA., 1994, 91, 3438-3442. (Pubitemid 24130252)
28. Shi, W.; Wymore, R.S.; Wang, H.S.; Pan, Z.; Cohen, I.S.; McKinnon, D.; Dixon, J.E. Identification of two nervous system-specific members of the erg potassium channel gene family. J. Neurosci., 1997, 17, 9423-9432. (Pubitemid 28006387)
29. + channels in excitable cells. J. Cell. Mol. Med., 2004, 8, 22-30. (Pubitemid 44145519)
30. Kr potassium channel. Cell, 1995, 81, 299-307.
31. Trudeau, M.; Warmke, J.W.; Ganetzky, B.; Robertson, G.A. hERG, A human inward rectifier in the voltage-gated potassium channel family. Science, 1995, 269, 92-95.
32. Roden, D.M. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin. Electrophysiol., 1998, 21(5), 1029-1034.
33. Roden, D.M.; Yang, T. Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve. Circulation, 2005, 112(10), 1376-1378. (Pubitemid 41291759)
34. Roden, D.M. Long QT syndrome: reduced repolarization reserve and the genetic link. J. Intern. Med., 2006, 259(1), 59-69.
35. + channels. J. Gen. Physiol., 2003, 121, 583-598. (Pubitemid 36682922)
36. Jiang, M.; Dun, W.; Fan, J.S.; Tseng, G.N. Use-dependent 'agonist' effect of azimilide on the hERG channel. J. Pharmacol. Exp. Ther., 1999, 291(3), 1324-1336.
37. Hosaka, Y.; Iwata, M.; Kamiya, N.; Yamada, M.; Kinoshita, K.; Fukunishi, Y.; Tsujimae, K.; Hibino, H.; Aizawa, Y.; Inanobe, A.; Nakamura, H.; Kurachi, Y. Mutational analysis of block and facilitation of hERG current by a class III anti-arrhythmic agent, nifekalant. Channels, 2007, 1(3), 198-208.
38. + current by almokalant in rabbit ventricular myocytes. Circ. Res., 1993, 73, 857-868. (Pubitemid 23306131)
39. Fermini, B.; Fossa, A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov., 2003, 2, 439-447. (Pubitemid 37361725)
40. Malykhina, A.P.; Shoeb, F.; Akbarali, H.I. Fenamate-induced enhancement of heterologously expressed hERG currents in Xenopus oocytes. Eur. J. Pharmacol., 2002, 452, 269-277. (Pubitemid 35279429)
41. Farrugia, G.; Rae, J.L.; Sarr, M.G.; Szurszewski, J.H. Potassium current in circular smooth muscle of human jejunum activated by fenamates. Am. J. Physiol., 1993, 265, G873-G879.
42. Farrugia, G., Rae, J.L.; Szurszewski, J.H.; Characterization of an outward potassium current in canine jejunal circular smooth muscle and its activation by fenamates. J. Physiol., 1993, 468, 297-310. (Pubitemid 23254446)
43. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol. Pharmacol., 1998, 54, 695-703. (Pubitemid 28480973)
44. Stumpff, F.; Boxberger, M.; Thieme, H.; Strauss, O.; Wiederholt, M. Flufenamic acid enhances current through maxi-K channels in the trabecular meshwork of the eye. Curr. Eye Res., 2001, 22, 427-437. (Pubitemid 34253201)
45. - channels in Xenopus oocytes. Mol. Pharmacol., 1990, 37, 720-724. (Pubitemid 20171508)
46. + channel. Mol. Pharmacol., 2005, 67(3), 827-836. (Pubitemid 40365330)
47. Perry, M.; Sachse, F.B.; Sanguinetti, M.C. Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator. Proc. Natl. Acad. Sci. USA., 2007, 104(34), 13827-13832. (Pubitemid 350003405)
48. + channels defined by high-affinity metal bridges. Nature, 2004, 428, 864-868. (Pubitemid 38529502)
49. Liu, J.; Zhang, M.; Jiang, M.; Tseng, G.N. Structural and functional role of the extracellular S5-P linker in the hERG potassium channel. J. Gen. Physiol., 2002, 120, 723-737. (Pubitemid 35332590)
50. Perry, M.; Sanguinetti, M.C. A single amino acid difference between Ether-a-go-go- related gene channel subtypes determines differential sensitivity to a small molecule activator. Mol. Pharmacol., 2008, 73, 1044-1051. (Pubitemid 351439186)
51. Zhou, J.; Augelli-Szafran, C.E.; Bradley, J.A.; Chen, X.; Koci, B.J.; Volberg, W.A.; Sun, Z.; Cordes, J.S. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol. Pharmacol., 2005, 68, 876-884. (Pubitemid 41206044)
52. Patel, C.; Antzelevitch, C. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm., 2008, 5(4), 585-590.
53. Wang, S.; Morales, M.J.; Liu, S.; Strauss, H.C.; Rasmusson, R.L. Time, voltage and ionic concentration dependence of rectification of h-erg expressed in Xenopus oocytes. FEBS Lett., 1996, 389, 167-173. (Pubitemid 26226493)
54. Gordon, E.; Lozinskaya, I.M.; Lin, Z.; Semus, S.F.; Blaney, F.E.; Willette, R.N.; Xu, X. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5- ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels. Mol. Pharmacol., 2008, 73(3), 639-651. (Pubitemid 351397869)
55. Lalik, P.H.; Krafte, D.S.; Volberg, W.A.; Ciccarelli, R.B. Characterization of endogenous sodium channel gene expressed in Chinese hamster ovary cells. Am. J. Physiol., 1993, 264, C803-C809. (Pubitemid 23118099)
56. Yu, S.P.; Kerchner, G.A. Endogenous voltage-gated potassium channels in human embryonic kidney (HEK293) cells. J. Neurosci. Res., 1998, 52, 612-617.
57. Ks potassium channel. Nature, 1996, 384, 80-83. (Pubitemid 26374592)
58. Xu, X.; Recanatini, M.; Roberti, M.; Tseng, G.N. Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243). Mol. Pharmacol., 2008, 73(6), 1709-1721. (Pubitemid 351724359)
59. Kamiya, K.; Niwa, R.; Mitcheson, J.S.; Sanguinetti, M.C. Molecular determinants of hERG channel block. Mol. Pharmacol., 2006, 69, 1709-1716.
60. Su, Z.; Limberis, J.; Souers, A.; Kym, P.; Mikhail, A.; Houseman, K.; Diaz, G.; Liu, X.; Martin, R.L.; Cox, B.F.; Gintant, G.A. Electrophysiologic characterization of a novel hERG channel activator. Biochem. Pharmacol., 2009, 77(8), 1383-1390.
61. Gerlach, A.C.; Stoehr, S.J.; Castle, N.A. Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574). Mol Pharmacol., 2010, 77(1), 58-68.
62. + channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation. J. Physiol., 1998, 509, 129-137. (Pubitemid 28252017)
63. Hill, A.P.; Campbell, T.J.; Bansal, P.S.; Kuchel, P.W.; Vandenberg, J.I. The S631A mutation causes a mechanistic switch in the block of hERG channels by CnErg1. Biophys. J., 2007, 93, L32-L34. (Pubitemid 47437568)
64. Gessner, G.; Macianskiene, R.; Starkus, J.G.; Schönherr, R.; Heinemann, S.H. The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism. Eur. J. Pharmacol., 2010, 632(1-3), 52-59.
65. Carlsson, B.; Singh, B.N.; Temciuc, M.; Nilsson, S.; Li, Y.-L.; Mellin, C.; Malm, J. Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone. J. Med. Chem., 2002, 45, 623-630. (Pubitemid 34145708)
66. Mubagwa, K.; Macianskiene, R.; Viappiani, S.; Gendviliene, V.; Carlsson, B.; Brandts, B. KB130015, a new amiodarone derivative with multiple effects on cardiac ion channels. Cardiovasc. Drug Rev., 2003, 21, 216-235. (Pubitemid 37243526)
67. + channels. Circ. Res., 1998, 82, 386-395. (Pubitemid 28101196)
68. Zeng, H.; Lozinskaya, I.M.; Lin, Z.; Willette, R.N.; Brooks, D.P.; Xu, X. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator. J. Pharmacol. Exp. Ther., 2006, 319(2), 957-962.
69. Gschwendt, M., Kittstein, W.; Marks, F. Elongation factor-2 kinase: effective inhibition by the novel protein kinase inhibitor rottlerin and relative insensitivity towards staurosporine. FEBS Lett., 1994, 338, 85-88. (Pubitemid 24047787)
70. Gschwendt, M.; Muller, H.J.; Kielbassa, K.; Zang, R.; Kittstein, W.; Rincke, G.; Marks, F. Rottlerin, a novel protein kinase inhibitor. Biochem. Biophys. Res. Commun., 1994, 199, 93-98. (Pubitemid 24179919)
71. Zakharov, S.I.; Morrow, J.P.; Liu, G.; Yang, L.; Marx, S.O. Activation of the BK (SLO1) potassium channel by mallotoxin. J. Biol. Chem., 2005, 280, 30882-30887. (Pubitemid 41291819)
72. + channel gating by activation of a G protein-coupled receptor and protein kinase C. J. Physiol. (Lond.), 1998, 511, 333-346. (Pubitemid 28444606)
73. Thomas, D.; Zhang, W.; Wu, K.; Wimmer, A.B.; Gut, B.; Wendt-Nordahl, G.; Kathofer, S.; Kreye, V.A.; Katus, H.A.; Schoels, W.; Kiehn, J.; Karle, C.A. Regulation of hERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein. Cardiovasc. Res., 2003, 59, 14-26. (Pubitemid 36776369)
74. Davies, S.P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J., 2000, 351, 95-105.
75. Kr activation in a cellular model of LQT3. Heart Rhythm., 2009, 6(1), 100-106.
76. Schreibmayer, W.; Kazerani, H.; Tritthart, H.A. A mechanistic interpretation of the action of toxin II from Anemonia sulcata on the cardiac sodium channel. Biochim. Biophys. Acta., 1987, 901, 273-282.
77. Lu, H.R.; Vlaminckx, E.; Hermans, A.N.; Rohrbacher, J.; Van Ammel, K.; Towart, R.; Pugsley, M.; Gallacher, D.J. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. B r. J. Pharmacol., 2008, 154(7), 1427-1438.
78. - conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease. Blood, 2001, 97, 1451-1457. (Pubitemid 32183772)
79. Hansen, R.S.; Diness, T.G.; Christ, T.; Wettwer, E.; Ravens, U.; Olesen, S.P.; Grunnet, M. Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5- yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea]. Mol. Pharmacol., 2006, 70(4), 1319-1329. (Pubitemid 44435984)
80. Hansen, R.S.; Olesen, S.P.; Grunnet, M. Pharmacological activation of rapid delayed rectifier potassium current suppresses bradycardia-induced triggered activity in the isolated guinea pig heart. J. Pharmacol. Exp. Ther., 2007, 321(3), 996-1002. (Pubitemid 46762682)
81. Hondeghem, L.M.; Carlsson, L.; Duker, G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation, 2001, 103(15), 2004-2013. (Pubitemid 32322230)
82. Pankucsi, C.; Varró, A.; Nánási, P. P. Three distinct components of the negative inotropic action of lidocaine in dog Purkinje fiber. Gen. Pharmacol., 1996, 27, 69-71. (Pubitemid 26076851)
83. Honerjäger, P.; Loibl, E.; Steidl, I.; Schonsteiner, G.; Ulm, K. Negative inotropic effects of tetrodotoxin and seven class 1 antiarrhythmic drugs in relation to sodium channel blockade. Naunyn-Schmiedeberg's Arch. Pharmacol., 1986, 332, 184-195. (Pubitemid 16134508)
84. 2+ current. Circ. Res., 1989, 64, 977-990. (Pubitemid 19117651)
85. Kr Agonist NS3623 on cardiac electrophysiology of the guinea pig. J. Cardiovasc. Pharmacol., 2008, 52(1), 35-41.
86. Hamlin, R.L.; Kijtawornrat, A.; Keene, B.W.; Hamlin, D.M. QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles. Toxicol. Sci., 2003, 76, 437-442. (Pubitemid 38035437)
87. K,s in rabbit sinoatrial node cells. J. Physiol., 2001, 535, 703-714. (Pubitemid 32894483)
88. Picker, O.; Scheeren, T.W.; Arndt, J.O. Inhalation anaesthetics increase heart rate by decreasing cardiac vagal activity in dogs. B r. J. Anaesth., 2001, 87, 748-754. (Pubitemid 33069566)
89. Hansen, R.S.; Diness, T.G.; Christ, T.; Demnitz, J.; Ravens, U.; Olesen, S.P.; Grunnet, M. Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Mol. Pharmacol., 2006, 69(1), 266-277. (Pubitemid 43048913)
90. Kr impairs conduction in guinea pig hearts. J. Cardiovasc. Electrophysiol., 2010, 21(8), 923-929.
91. Qu, Z.; Weiss, J.N.; Garfinkel, A. Cardiac electrical restitution properties and stability of reentrant spiralwaves: A simulation study. Am. J. Physiol., 1999, 276, H269-H283. (Pubitemid 29065646)
92. Diness, T.G.; Hansen, R.S.; Olesen, S.P.; Grunnet, M. Frequency-dependent modulation of KCNQ1 and hERG1 potassium channels. Biochem. Biophys. Res. Commun., 2006, 343(4), 1224-1233.
93. Casis, O.; Olesen, S.P.; Sanguinetti, M.C. Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol. Pharmacol., 2006, 69, 658-665. (Pubitemid 43121963)
94. Lees-Miller, J.P.; Duan, Y.; Teng, G.Q.; Duff, H.J. Molecular determinant of high-affinity dofetilide binding to hERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol. Pharmacol., 2000, 57, 367-374. (Pubitemid 30084514)
95. Sanchez-Chapula, J.A.; Ferrer, T.; Navarro-Polanco, R.A.; Sanguinetti, M.C. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol. Pharmacol., 2003, 63, 1051-1058. (Pubitemid 36529923)
96. + channel block. J. Biol. Chem., 2002, 277, 23587-23595. (Pubitemid 34952195)
97. Fernandez, D.; Ghanta, A.; Kauffman, G.W.; Sanguinetti, M.C. Physicochemical features of the hERG channel drug binding site. J. Biol. Chem., 2004, 279, 10120-10127. (Pubitemid 38372616)
98. + channel activation by 1,3-Bis-(2-hydroxy-5- trifluoromethyl-phenyl)-urea (NS1643). Mol. Pharmacol., 2011, 79(1), 1-9.
99. Elmedyb, P.; Olesen, S.P.; Grunnet, M. Activation of ERG2 potassium channels by the diphenylurea NS1643. Neuropharmacology, 2007, 53(2), 283-294. (Pubitemid 47187454)
100. Killeen, M.J.; Thomas, G.; Olesen, S.P.; Demnitz, J.; Stokoe, K.S.; Grace, A.A.; Huang, C.L. Effects of potassium channel openers in the isolated perfused hypokalaemic murine heart. Acta Physiol. (Oxf)., 2008, 193(1), 25-36. (Pubitemid 351490258)
101. Killeen, M.J.; Thomas, G.; Gurung, I.S.; Goddard, C.A.; Fraser, J.A.; Mahout-Smith, M.P.; Colledge, W.H.; Grace, A.A.; Huang, C.L. Arrhythmogenic mechanisms in the isolated perfused hypokalaemic murine heart. Acta Physiol., 2007, 189, 33-46. (Pubitemid 46092428)
102. Diness, T.G.; Yeh, Y.H.; Qi, X.Y.; Chartier, D.; Tsuji, Y.; Hansen, R.S.; Olesen, S.P.; Grunnet, M.; Nattel, S. Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. Cardiovasc. Res., 2008, 79(1), 61-69. (Pubitemid 351881940)
103. Tsuji, Y.; Zicha, S.; Qi, X-Y.; Kodama, I.; Nattel, S. Potassium channel subunit remodeling in rabbits exposed to long-term bradycardia or tachycardia: discrete arrhythmogenic consequences related to differential delayed-rectifier changes. Circulation, 2006, 113, 345-355. (Pubitemid 43803195)
104. Carlsson, L.; Abrahamsson, C.; Andersson, B.; Duker, G.; Schiller-Linhardt, G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc. Res., 1993, 27, 2186-2193. (Pubitemid 24034733)
105. Peitersen, T.; Grunnet, M.; Benson, A.P.; Holden, A.V.; Holstein-Rathlou, N.H.; Olesen, S.P. Computational analysis of the effects of the hERG channel opener NS1643 in a human ventricular cell model. Heart Rhythm., 2008, 5(5), 734-741.
106. Ten Tusscher, K.H.; Noble, D.; Noble, P.J.; Panfilov, A.V. A model for human ventricular tissue. Am. J. Physiol. Heart Circ. Physiol., 2004, 286, H1573-H1589. (Pubitemid 38381170)
107. Szentandrássy, N.; Bányász, T.; Bíró, T.; Szabó, G.; Tóth, I.B.; Magyar, J.; Lázár, J.; Varró, A.; Kovács, L.; Nánási, P. P. Apico-basal inhomogeneity in distribution of ion channels in canine and human ventricular myocardium. Cardiovasc. Res., 2005, 65, 851-860.
108. Szabó, G.; Szentandrássy, N.; Bíró, T.; Tóth. I.B.; Czifra, G.; Magyar, J.; Bányász, T.; Varró, A.; Kovács, L.; Nánási, P. P. Asymmetrical distribution of ion channels in canine and human left ventricular wall: epicardium versus midmyocardium. Pflügers Arch., 2005, 450, 307-316. (Pubitemid 41204177)
109. Bányász, T.; Magyar, J.; Körtvély, Á.; Szigeti, Gy.; Szigligeti, P.; Papp, Z.; Mohácsi, A.; Kovács, L.; Nánási, P. P. Different effects of endothelin-1 on calcium and potassium currents in canine ventricular cells. Naunyn Schmiedeberg's Arch. Pharmacol., 2001, 363, 383-390. (Pubitemid 32247121)
110. Ks to ventricular repolarization in canine myocytes. Pflügers Arch, 2006, 452, 698-706. (Pubitemid 44337905)
111. Magyar, J.; Szentandrássy, N.; Bányász, T.; Kecskeméti, V.; Nánási P.P. Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes. Naunyn Schmiedeberg's Arch. Pharmacol, 2004, 370, 203-210. (Pubitemid 39361856)
112. Fischmeister, R.; DeFelice, L.J.; Ayer, R.K.; Levi, R.; DeHaan, R.L. Channel currents during spontaneous action potentials in embryonic chick heart cells. The action potential patch clamp. Biophys. J., 1984, 46, 267-271.
113. Bányász, T.; Fülöp, L.; Magyar, J.; Szentandrássy, N.; Varró, A.; Nánási, P.P. Endocardial versus epicardial differences in L-type calcium current in canine ventricular myocytes studied by action potential voltage clamp. Car- diovasc. Res., 2003, 58, 66-75. (Pubitemid 36351623)
114. + currents in canine cardiomyocytes: their role in ventricular repolarization. Acta Physiol. (Scand), 2007, 190, 189-198. (Pubitemid 46934656)
115. El-Sherif, N.; Turitto, G. The long QT syndrome and torsade de pointes. Pacing Clin. Electrophysiol, 1999, 22, 91-110. (Pubitemid 29066584)
116. + channels and drug-acquired long QT syndrome. Therapie, 2000, 55, 185-193. (Pubitemid 30319280)
117. Priori, S.G.; Napolitano, C. Genetics of cardiac arrhythmias and sudden cardiac death. Ann. N.Y. Acad. Sci, 2004, 1015, 96-110. (Pubitemid 38879482)
118. Roden, D.M.; Viswanathan, PC. Genetics of acquired long QT syndrome. J. Clin. Invest, 2005, 115, 2025-2032. (Pubitemid 41134138)
119. Harmati, G.; Bányász, T.; Bárándi, L.; Szentandrássy, N.; Horváth, B.; Szabó, G.; Szentmiklósi, J.A.; Szénási, G.; Nánási, P.P.; Magyar, J. Effects of β-adrenoceptor stimulation on delayed rectifier K(+) currents in canine ventricular cardiomyocytes. Br. J. Pharmacol, 2011, 162(4), 890-896.
120. George, A.L. Jr. Restoring repolarization in LQT3. Heart Rhythm., 2009, 6(1), 107-108.
121. Brugada, R.; Hong, K.; Cordeiro, J.M.; Dumaine, R. Short QT syndrome. CMAJ, 2005, 173, 1349-1353.
122. Bjerregaard, P.; Jahangir, A.; Gussak, I. Targeted therapy for short QT syndrome. Expert Opin. Ther. Targets, 2006, 10, 393-399.
123. Gussak, I; Brugada, P.; Brugada, J.; Wright, R.S.; Kopecky, S.L.; Chaitman, B.R.; Bjerregaard, P. Idiopathic short QT interval: a new clinical syndrome? Cardiology, 2000, 94, 99-102. (Pubitemid 32110328)
124. Gaita, F.; Giustetto, C; Bianchi, F.; Wolpert, C; Schimpf, R.; Riccardi, R.; Grossi, S.; Richiardi, E.; Borggrefe, M. Short QT syndrome: a familial cause of sudden death. Circulation, 2003, 108, 965-970. (Pubitemid 37048226)
125. Schimpf, R.; Wolpert, C; Gaita, F.; Giustetto, C; Borggrefe, M. Short QT syndrome. Cardiovasc. Res., 2005, 67, 357-366. (Pubitemid 41019545)
126. Grunnet, M. Repolarization of the cardiac action potential. Does an increase in repolarization capacity constitute a new anti-arrhythmic principle? Acta Physiol (Oxf.), 2010, 198(Suppl. 676), 1-48.